Clinical application of alpha fetoprotein combined with abnormal prothrombin in detecting primary liver cancer

Objective To investigate the clinical value of serum alpha fetoprotein(AFP) combined with abnormal prothrombin(PIVKA-Ⅱ) in the detection of primary liver cancer. Methods From May 2017 to October 2017, 80 cases of primary liver cancer in Department of Hepatobiliary Surgery of Deyang People's Hospital, 100 cases of non HCC patients(including chronic liver disease, cirrhosis, metastatic liver cancer) were selected, and another 100 healthy people were selected as control group.The levels of serum AFP and PIVKA-Ⅱ were detected by SIEMENS XP automatic immunoassay analyzer and lumipulseg1200 automatic immune analyzer respectively.All data were analyzed by SPSS17.0 analysis software. Results Comparison between primary liver cancer and non-primary liver cancer: the levels of serum AFP and PIVKA-Ⅱ(F=1.763; F=1.788, sig=0.000, P<0.05). Comparison between non-primary liver cancer and normal group: the levels of serum AFP and PIVKA-Ⅱ(F=0.896; F=0.346, sig=0.000, P<0.05). Serum AFP had a sensitivity of 75.0% and a specificity of 71.5% in the diagnosis of primary liver cancer, while PIVKA-Ⅱ had a sensitivity of 82.0% and a specificity of 78.7%.The diagnosis sensitivity and specificity of AFP combined with PIVKA-Ⅱ reached to 92.0% and 95.0%.The sensitivity of AFP combined with PIVKA-Ⅱ in the diagnosis of primary liver cancer had statistically significant differences compared with AFP and PIVKA-Ⅱ alone(χ2=4.112, P=0.008; χ2=2.991, P=0.010). Conclusion Combined detection of serum AFP and PIVKA-II has important clinical significance in the diagnosis of primary liver cancer. Key words: Liver Neoplasms; Alpha-fetoproteins; Prothrombin